Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
UK body NICE (The National Institute for Health and Care Excellence) has recommended olaparib (also known as Lynparza, and manufactured by AstraZeneca) for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube and peritoneal cancer.
The drug is for cancers in adults who have tested positive for the BRCA1 or BRCA2 mutations, and whose disease has responded to platinum-based chemotherapy.
Specifically, the recommendations say that olaparib should be available for people only if they have had 3 or more courses of platinum-based chemotherapy and the drug cost of olaparib for people who remain on treatment after 15 months is met by the company.
Source: NICE
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.